- About
- Events
- Resource Center
Archives
Assessing Pain & Its Impact In Autosomal Dominant Polycystic Kidney Disease (ADPKD): The ADPKD Pain & Discomfort Scale (ADPKD – PDS)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Assessing Pain & Its Impact In Autosomal Dominant Polycystic Kidney Disease (ADPKD): The ADPKD Pain & Discomfort Scale (ADPKD – PDS)
Background
Autosomal Dominant Polycystic Kidney Disease (ADPKD), an inherited progressive kidney disease, is the fourth leading cause of kidney failure in the US. Approximately 60% of primary complaints for ADPKD patients involved pain.1 Pain can be described as sharp, dull, acute and/or chronic, depending on the source.1 Patients have shared that pain and their large cystic kidneys often limited their daily activities, causing mental and physical fatigue.2 The Autosomal Dominant Polycystic Kidney Disease Pain & Discomfort Scale (ADPKD-PDS) has been developed and validated as a patient-reported outcomes (PRO) tool.2 While pain continues to be a challenging issue for patients with ADPKD and their health care teams, utilizing a validated tool such as the ADPKD-PDS can facilitate patient-health care professionals’ discussions about ADPKD-associated pain and its impact on patients and their families.2Did you Know?
- Individuals with ADPKD have identified inadequate pain management and trivialization of their pain by physicians as key concerns, pointing to the need for tools to address ADPKD-related pain.3
- The ADPKD-PDS tool was developed through a multi-step collaboration involving 26 clinical experts and 298 patient participants (46 patient focus groups across 18 countries).
Why Attend This Webinar?
- Join us for this webinar to learn more about the impact of pain in patients with ADPKD and how the new ADPKD-PDS tool can enable standardized assessment of the severity and impact of pain/discomfort in clinical trials and practice settings
What You Will Learn
- Why evaluate pain in ADPKD?
- Development process of the ADPKD-PDS
- Types of pain identified and evaluated in this PRO tool
- Bajwa ZH et al. Kidney Int. 2004;66:1561-9.
- Oberdhan DO et al. Clin J Am Soc Nephrol. 2023;18:213-22.
- Cho Y et al. Am J Kidney Dis. 2021;77:255-63.
Featuring
Pranav Garimella, MBBS, MPH, FASN
Associate Professor of MedicineUniversity of California San Diego*
Dr Garimella is an Associate Professor of Clinical Medicine and Nephrology at UC San Diego. He is the Director of Acute Dialysis Services at UC San Diego Health and the founding Director of the UCSD PKD Center of Excellence. He received his training in India, Chicago, and completed his fellowship at Tufts University, training in clinical nephrology with a focus on polycystic kidney disease with Dr Ron Perrone. His research endeavors have led to multiple NIH-funded studies and numerous peer-reviewed publications on the topic of kidney diseases. He has an ongoing NIH grant for his research elucidating aspects of kidney disease and has been the recipient of a multitude of teaching and clinical excellence awards. He is also involved in initiatives to develop programs specifically targeted at minority populations in an effort to improve health literacy and potentially clinical outcomes
Moderator
Josh Gariboldi, PharmD, BCPS
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Josh Gariboldi, PharmD, BCPS joined Otsuka in January 2021 and is a Medical Science Liaison on our Nephrology East Team, covering the Carolinas and Tennessee. Dr Gariboldi earned his Doctor of Pharmacy degree from the University of Florida in 2012. He has more than eight years of experience as a clinical pharmacist in both the community and hospital settings, most recently at Bon Secours Mercy Health St. Francis Hospital in Greenville, SC. Dr Gariboldi served as a preceptor with Presbyterian College School of Pharmacy, where he instructed students on Advanced Pharmacy Practice rotations. He holds board certifications in both pharmacotherapy and medical affairs.
*Dr Pranav Garimella is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Josh Gariboldi is an employee of OPDC.
Registration
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - Events
